get a key
steadybase-$ company FBIO
account_id none on file
legal_name Fortress Biotech, Inc.
ticker FBIO
cik 1429260
domain fortressbiotech.com
entry_point_account_id none on file
name Fortress Biotech Inc.
exchange Nasdaq
sector Health Care
hq Bay Harbor Islands, FL, United States
calls 0 filings 22 executives 3 family 0
why_nownone on file
callsnone on file
filings
In connection with the termination, Avenue repurchased shares previously issued to AnnJi for nominal consideration and paid $ 0.2 million for legal expense reimbursement, which was accounted for as consideration payable to a customer and reduced revenue recognized.

filing / Aug 13, 2026 / receipt

As of June 30, 2026 and December 31, 2025, the Company had $ 1.2 million of restricted cash representing pledges to secure letters of credit in connection with certain office leases.

filing / Aug 13, 2026 / receipt

The Desk Share Agreement between the Company and TGTX, as amended, required TGTX to pay 65 % of the average annual rent for the Company’s New York, NY office space.

filing / Aug 13, 2026 / receipt

The increase of $2.7 million, or 26%, at Fortress is due to increased personnel and severance expenses of $2.1 million, Cyprium’s increased personnel-related expenses of $3.0 million and increased legal expense of $0.5 million, partially offset by decreased stock-based compensation at Fortress of $2.6 million related to fully vested LTIP grants in 2025, and decreased legal costs associated with the Checkpoint transac

filing / Aug 13, 2026 / receipt

A primary trend in the healthcare industry in the United States and elsewhere is cost containment. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirement

filing / Aug 13, 2026 / receipt

The implementation of any of the cost containment measures or other healthcare reforms discussed above may prevent us from being able to generate revenue, attain profitability or commercialize our products.

filing / Aug 13, 2026 / receipt

In connection with the termination, Avenue repurchased shares previously issued to AnnJi for nominal consideration and paid $ 0.2 million for legal expense reimbursement, which was accounted for as consideration payable to a customer and reduced revenue recognized.

filing / Aug 13, 2026 / receipt

As of June 30, 2026 and December 31, 2025, the Company had $ 1.2 million of restricted cash representing pledges to secure letters of credit in connection with certain office leases.

filing / Aug 13, 2026 / receipt

The Desk Share Agreement between the Company and TGTX, as amended, required TGTX to pay 65 % of the average annual rent for the Company’s New York, NY office space.

filing / Aug 13, 2026 / receipt

The increase of $2.7 million, or 26%, at Fortress is due to increased personnel and severance expenses of $2.1 million, Cyprium’s increased personnel-related expenses of $3.0 million and increased legal expense of $0.5 million, partially offset by decreased stock-based compensation at Fortress of $2.6 million related to fully vested LTIP grants in 2025, and decreased legal costs associated with the Checkpoint transac

filing / Aug 13, 2026 / receipt

A primary trend in the healthcare industry in the United States and elsewhere is cost containment. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirement

filing / Aug 13, 2026 / receipt

The implementation of any of the cost containment measures or other healthcare reforms discussed above may prevent us from being able to generate revenue, attain profitability or commercialize our products.

filing / Aug 13, 2026 / receipt

executives
David Jin Chief Financial Officer linkedin receipt
Malcolm Hoenlein director - receipt
Robyn Hunter Chief Financial Officer - receipt
familynone on file
upcoming
2026-11-13 earnings call scheduled ir
changes
2022-07-22 Vice President, appointed sec_8k
2017-06-30 Chief Financial Officer, appointed sec_8k
2014-02-26 director, appointed sec_8k
mcp_package_hint
steadybase-$